RT Journal Article
SR Electronic
T1 Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20148395
DO 10.1101/2020.07.07.20148395
A1 Aschenbrenner, Anna C.
A1 Mouktaroudi, Maria
A1 Krämer, Benjamin
A1 Antonakos, Nikolaos
A1 Oestreich, Marie
A1 Gkizeli, Konstantina
A1 Nuesch-Germano, Melanie
A1 Saridaki, Maria
A1 Bonaguro, Lorenzo
A1 Reusch, Nico
A1 Baßler, Kevin
A1 Doulou, Sarandia
A1 Knoll, Rainer
A1 Pecht, Tal
A1 Kapellos, Theodore S.
A1 Rovina, Nikoletta
A1 Kröger, Charlotte
A1 Herbert, Miriam
A1 Holsten, Lisa
A1 Horne, Arik
A1 Gemünd, Ioanna D.
A1 Agrawal, Shobhit
A1 Dahm, Kilian
A1 Uelft, Martina van
A1 Drews, Anna
A1 Lenkeit, Lena
A1 Bruse, Niklas
A1 Gerretsen, Jelle
A1 Gierlich, Jannik
A1 Becker, Matthias
A1 Händler, Kristian
A1 Kraut, Michael
A1 Theis, Heidi
A1 Mengiste, Simachew
A1 Domenico, Elena De
A1 Schulte-Schrepping, Jonas
A1 Seep, Lea
A1 Raabe, Jan
A1 Hoffmeister, Christoph
A1 ToVinh, Michael
A1 Keitel, Verena
A1 Rieke, Gereon
A1 Talevi, Valentina
A1 Aziz, N. Ahmad
A1 Pickkers, Peter
A1 van de Veerdonk, Frank
A1 Netea, Mihai G.
A1 Schultze, Joachim L.
A1 Kox, Matthijs
A1 Breteler, Monique M.B.
A1 Nattermann, Jacob
A1 Koutsoukou, Antonia
A1 Giamarellos-Bourboulis, Evangelos J.
A1 Ulas, Thomas
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.07.20148395.abstract
AB The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases calls for a better characterization and understanding of the changes in the immune system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a collection of over 2,800 samples derived from 11 different viral infections, inflammatory diseases and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host.Competing Interest StatementThe authors have declared no competing interest.Funding StatementACA was supported by an intramural grant from the Department of Genomics & Immunoregulation at the LIMES Institute. The work of JLS and MMBB was supported by the German Research Foundation (DFG) under Germanys Excellence Strategy EXC2151 390873048 as well as by the Diet-Body-Brain Competence Cluster in Nutrition Research funded by the Federal Ministry of Education and Research (grant numbers 01EA1410C and 01EA1809C). JLS was further supported by the DFG under SCHU 950/8-1; GRK 2168, TP11; SFB704, the EU project SYSCID under grant number 733100. MGN was supported by a Spinoza grant of the Netherlands Organisation for Scientific Research and an ERC Advanced Grant (833247). The study was funded in part by the Hellenic Institute for the Study of Sepsis. EJG-B received funding from the FrameWork 7 program HemoSpec and from the Horizon2020 Marie-Curie project European Sepsis Academy (granted to the National and Kapodistrian University of Athens). JN was supported by the DFG (SFB TR57, SPP1937), the DZIF, and the Hector-Foundation (M89).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were conducted under the 23/12.08.2019 approval of the Ethics Committee of Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON University General Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study, including transcriptome data from 60 patients at multiple time points who granted informed consent to share such data, are made available at the European Genome-Phenome Archive (EGA) under accession number EGAS00001004503, which is hosted by the EBI and the CRG.